TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06570538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 300 mL of 0.25% ropivacaine, the mode was intermittent pumping, and the parameters were set as follows: 30 mL of the first dose, 5 mL/h of the background dose, and 10 mL of the pumping every 6h for the first 24 hours after the operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil 2.0 μg/kg, 0.9% saline diluted to 100 mL, background dose of 2 ml/h, no loading dose, activated after extubation and continued until 48 hours postoperatively.
Study: NCT06569927

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Utilization of a perioperative position management protocol for congenital microtia patients based on the ADDIE model.
Description: Key elements included formation of a multidisciplinary team，perioperative postural management, preoperative sleeping posture adaptability training, neck movement training, standardization of head position angles and head suspension time during surgery, use of protective headrests, attention to transfer and handover procedures, and specially designed pillows.
Study: NCT06570889

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol D3
Description: Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Oral intake of 1 capsule per day from week 22-26 in pregnancy to 1 week after delivery
Study: NCT06122597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ConcenTrace
Description: The product contains concentrated seawater from Utah's inland sea.
Study: NCT06571097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoﬂoxacin
Description: 0.5g/day for 2 weeks
Study: NCT06062485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib+Toripalimab+AG
Description: This is a single-arm, prospective, exploratory clinical study of unresectable or relapsing metastatic ampullary tumors who were not systematically treated with surufatinib in combination with PD-1 antibody and AG regimen.Until the investigator assesses loss of clinical benefit, unacceptable toxicity, decision by the investigator or subject to withdraw treatment, or death, whichever comes first.The AG regimen does not exceed 8 cycles, and maintenance therapy with surufatinib combined with toripalimab can be continued if the patient has not progressed after 8 cycles. The treatment period was 21 days; Tumor treatment and survival status were recorded until disease progression (RECIST 1.1) or death (during patient treatment).~Surufatinib (200mg，qd，Q3W）；Toripalimab(240mg IV d1, Q3W)；AG（Albumin-bound paclitaxel: 125mg/m2，IV，d1，d8，Q3W）Gemcitabine: 1000 mg/m2, IV，d1，d8，Q3W）
Study: NCT05353179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperizumab injection
Description: Meperizumab injection is a humanized monoclonal antibody of IgG1 injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NUCALA®
Description: NUCALA® is a humanized monoclonal antibody of IgG1 injection
Study: NCT05004077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMIODARONE
Description: Assess the effectiveness of different dosing strategies of amiodarone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMIODARONE
Description: Assess the effectiveness of different dosing strategies of amiodarone.
Study: NCT05961735

Intervention type: OTHER
Intervention: PECS II Block
Description: The Pecs II block is applied to the patients after induction of anesthesia .

Intervention type: OTHER
Intervention: Combined Serratus Anterior Plane Block
Description: Combined Serratus Anterior Plane Block is applied to the patients after induction of anesthesia .
Study: NCT04973319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Each subject in the test group will receive the test drug (pyrotinib) for 52 weeks, and will be followed up for at least 3 years from the start of randomization, until disease recurrence, intolerable toxicity, withdrawal of informed consent, or termination of the medication as per the investigator's judgment.

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab
Description: Each enrolled subject will complete at least ≥ 24 weeks (8 drug delivery cycles) of trastuzumab combined with pertuzumab in the neoadjuvant and/or adjuvant treatment phase.
Study: NCT04628741

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Coaching Model
Description: This is a behavioral intervention which includes metacognitive strategy training and personalized strategy and external aid use training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Apprenticeship Approach
Description: This is a behavioral intervention which includes explicit education about traumatic brain injury, its symptoms, and individuals who may provide assistance post-injury, metacognitive strategy training and personalized strategy and external aid use training.
Study: NCT05002881

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moringa oleifera (E-HS-01)
Description: One capsule to be taken stat

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moringa oleifera (E-HS-01)
Description: One capsule to be taken stat

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One capsule to be taken stat

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule to be taken stat
Study: NCT05704673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nalbuphine on N and V and pain with intrathecal morphine onInguinal hernia repair surgery. randomized, prospective, double blinded and placebo-controlled trial study.
Description: investigate the effect of Iv nalbuphine on postoperative nausea and vomiting and pain with intrathecal morphine on inguinal hernia repair surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nalbuphine on N and V and pain with intrathecal morphine onInguinal hernia repair surgery. randomized, prospective, double blinded and placebo-controlled trial study.
Description: investigate the effect of Iv nalbuphine on postoperative nausea and vomiting and pain with intrathecal morphine on inguinal hernia repair surgery.
Study: NCT04691544

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT)
Description: Delivered by enema
Study: NCT04841486

Intervention type: OTHER
Intervention: Data collection
Description: evaluation of women's stress

Intervention type: OTHER
Intervention: Data collection
Description: evaluation of women's stress
Study: NCT04962100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis of capacitation-associated tyrosine phosphorylation in human sperm by flow cytometry
Description: After the assessment of the macroscopic and microscopic characteristics of the sample, we will wash the sample and process it using three layers of density gradients.~In the case of samples for diagnostic analysis, the remaining volume will be incubated in at 37ºC, and 0.1-0.2 ml aliquots will be taken from the end of the processing at t0 (just before introducing the sample in the incubator), at t1 (after one hour of incubation) and at t3 (after 3 hours of incubation). Additionally, a sample will be taken after washing, prior to processing the sample with the density gradients. In the case of samples processed for insemination, an additional aliquot will be taken at the exact moment in which the insemination is carried out and the elapsed incubation time will be noted.~The evaluation of the capacitation will be carried out by analyzing the state of phosphorylation of tyrosines by flow cytometry.
Study: NCT06440837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB stress self-management health education
Description: The health education intervention program contains eight module topics: stress-related knowledge, the thinking and mentality under stress, social support, take care of your suffering, manage your difficult emotions, acceptance, embrace a better life, ending. One topic or session is delivered by weeks, each session lasting 30-40 minutes.
Study: NCT06056154

Intervention type: DEVICE
Intervention: LIO ASQELIO TM monofocal QLIO130C
Description: Intraocular lens (IOL) implant. All patients will have been treated as per standard clinical practice.
Study: NCT05092906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LP with complementary hypnoanalgesia
Description: The lumbar puncture technique will be identical to that of the group standard of care. Hypnosis will be performed by a health professional trained in this practice, in addition to the standard analgesic management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LP with standard of care
Description: The LP will be carried out according to the usual techniques without hypnosis.~Standard analgesic treatments will be used (except contraindications):~* EMLA (Lidocain+Prilocain) Cream/Patch~* Local anesthesia with lidocain chlorhydrate monohydrate 1% injectable~* Nitrous oxide
Study: NCT04767230

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Intervention
Description: A heart-healthy diet + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil in adjunct to medical treatment for 3 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: A heart-healthy diet + daily consumption of 30 grams of flaxseed + 25 mL/day of refined olive oil in adjunct to medical treatment for 3 months
Study: NCT05584124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency repetitive transcranial magnetic stimulation
Description: MAGSTIM Super Rapid2 Plus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency repetitive transcranial magnetic stimulation
Description: MAGSTIM Super Rapid2 Plus

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: MAGSTIM Super Rapid2 Plus
Study: NCT05364944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 4126
Description: Intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 4126
Description: Intramuscular (IM) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR
Description: Sandostatin LAR will be administered as IM injection as pre-study treatment dose prior to Debio 4126 administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR
Description: Sandostatin LAR will be administered as IM injection as pre-study treatment dose prior to Debio 4126 administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatuline ATG
Description: Somatulin ATG will be administered as deep subcutaneous (SC) injection as pre-study treatment dose prior to Debio 4126 administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatuline ATG
Description: Somatulin ATG will be administered as deep subcutaneous (SC) injection as pre-study treatment dose prior to Debio 4126 administration
Study: NCT06358638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab is a cytotoxic monoclonal antibody (IgG1k) to CD38 and is commercially approved to treat multiple myeloma. CD38 is expressed on several types of blood cells including B-cells, antibody-secreting plasma blasts and plasma cells. As a result, it has been used to treat antibody-mediated diseases, including children with antibody-mediated cytopenias post-HCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab is a cytotoxic monoclonal antibody (IgG1k) to CD38 and is commercially approved to treat multiple myeloma. CD38 is expressed on several types of blood cells including B-cells, antibody-secreting plasma blasts and plasma cells. As a result, it has been used to treat antibody-mediated diseases, including children with antibody-mediated cytopenias post-HCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus is an mTOR inhibitor immunosuppressant used to prevent organ transplant rejections as well as treat lymphangioleiomyomatosis and adults with perivascular epithelioid cell tumors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus is an mTOR inhibitor immunosuppressant used to prevent organ transplant rejections as well as treat lymphangioleiomyomatosis and adults with perivascular epithelioid cell tumors.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total body irradiation is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell transplantation. The radiation is given in a low dose so that normal tissues can repair themselves.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total body irradiation is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell transplantation. The radiation is given in a low dose so that normal tissues can repair themselves.
Study: NCT05334082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIFA 11+
Description: 15 progressive exercise drills for training preparation (warm-up)
Study: NCT06417489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy
Description: Henagliflozin Proline 10 mg qd+Regagliptin 100 mg qd+Metformin 500mg bid. The dose of metformin from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential treatment group
Description: Metformin, the dose from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day. After the fourth week of treatment, blood glucose levels were measured. For those whose blood glucose levels did not meet the standard (fasting blood glucose (FPG)\&gt;7mmol/L, postprandial blood glucose (PPG)\&gt;10mmol/L), 10 mg qd of Henagliflozin Prolinewas sequentially added. If the blood glucose levels did not meet the standard after 4 weeks of treatment (FPG\&gt;7mmol/L, PPG\&gt;10mmol/L), 100 mg qd of Ruigeliflozin was added
Study: NCT04744597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real execution of Fitts's law tasks
Description: Children will be training Fitts's law tasks of different difficulties. Once each task will be solved, they will receive a new, more demanding task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery of Fitts's law tasks
Description: Children will be training Fitts's law tasks of different difficulties, same as RE group but the exception of doing it mentally - motor imagery of Fitts's law tasks with eyes open.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skip counting
Description: Children in SCg will silently count (one number per second) in the same working blocks as both experimental groups with a task of saying the number they reached during each block - control condition to keep them mentally active at very low mental engagement.
Study: NCT04642261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills
Description: Identical in appearance to empagliflozin 10mg daily
Study: NCT06454773

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: NCT/NFT
Description: extract from black pepper and hemp hull

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NCT/NFT
Description: extract from black pepper and hemp hull
Study: NCT05021419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Streamlined protocol
Description: A streamlined drug protocol for optimizing heart failure medication

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Protocol
Description: Current standard optimization protocol as per NICE and ESC
Study: NCT05848141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: This is a single site center-based supervised exercise intervention.
Study: NCT04188665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MASL
Description: Patients treated with MASL lozenge

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients treated with placebo lozenge
Study: NCT04903314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xcopri
Description: Xcopri will be administered orally not to exceed 400mg/day adult equivalent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xcopri
Description: Xcopri will be administered orally not to exceed 400mg/day adult equivalent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xcopri
Description: Xcopri will be administered orally not to exceed 400mg/day adult equivalent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xcopri
Description: Xcopri will be administered orally not to exceed 400mg/day adult equivalent
Study: NCT05454176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Libre 2
Description: The unblinded FreeStyle Libre 2 CGM will be placed every two weeks during months 0-12 for the CGM Cohort. Patients will be taught to insert the sensor themselves.~They will be given a 1 month supply at each monthly clinic visit and extra sensors in case a sensor falls out early. Patients will be given SMBG test strips to test capillary glucose for confirmation of any CGM glucose level \<=60mg/dl. They will keep track of the number of times this is necessary. Patients will return used sensors at each clinic visit. The study team will upload the data to a study website. Patients and care providers will have access to unblinded sensor data for clinical use.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Device for SMBG and Libre Pro
Description: A glucose meter and sufficient teststrips for fingerpoke glucose monitoring 3x/day will be provided for months 1-6. This is standard-of-care in Uganda. Glucose meters will be downloaded monthly in clinic as per usual clinical practice.~DeviceBlinded CGM device: Libre Pro (blinded data collection device, not an intervention) The blinded FreeStyle Libre Pro CGM will be inserted at each monthly clinic visit to provide control data, months 0-6 for the Control Group. They will return all used sensors at each clinic visit. The study team will upload the data to a study website. Neither patients nor the local research teams will have access to the blinded sensor data for clinical use until the end of months 0-6 so as not to influence standard diabetes management. They will instead rely on SMBG values as per usual routine.~After the first 6 months they will receive Libre 2 CGM systems as described above for the intervention group.
Study: NCT04841304

Intervention type: DEVICE
Intervention: Loop recorder (Reveal LINQ, Medtronic)
Description: Implantation of a loop-recorder

Intervention type: DEVICE
Intervention: Loop recorder (Reveal LINQ, Medtronic)
Description: Implantation of a loop-recorder

Intervention type: DEVICE
Intervention: Continuous Glucose Measurement (G6, Dexcom)
Description: Monitoring with a continuous glucose monitor
Study: NCT06049043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention to Help Orient Men to Excel (IN-HOME)
Description: A multi module online training

Intervention type: OTHER
Group type: OTHER
Intervention: AARP's English Care at Home resource webpage
Description: Caregiver information from the American Association of Retired Persons
Study: NCT05352100

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Therapeutic Vibration Device
Description: The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
Study: NCT04810169

Intervention type: DEVICE
Intervention: Smart inhaler
Description: * Automatic record (number of actuations and their timing) of the use of the emergency treatment through the smart inhaler~* Questionnaire sent to the parents at each use of the smart inhaler to get information regarding the reason of use and the efficacy of the treatment given
Study: NCT06529406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: De-escalation of anti-CD20 treatment using ozanimod.
Study: NCT05341843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Description: sertraline at the intended dose of 50 mg twice daily for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a placebo in the form of multivitamin tablets similar to the experimental drugs with the same regimen (one tablet /day for 8 weeks)
Study: NCT04841304

Intervention type: DEVICE
Intervention: Continuous Glucose Measurement (G6, Dexcom)
Description: Monitoring with a continuous glucose monitor
Study: NCT05314166

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: meditation practice
Description: Description: meditation practice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: meditation practice
Description: Description: meditation practice
Study: NCT06200584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Antipsychotic Agent
Study: NCT05178758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: Patients in the intervention (VR) group will receive a series of occupational and physical therapy rehabilitation training using the VR system. All training is consists of daily activities oriented by an occupational therapist, including grasp, grip, pinch, gross, and finger-hand coordination movement. Each training will take around 1 hour for one session per day 5 times per week over a maximum of 4 weeks. The training presented a one-on-one that allowed interaction between instructor (or VR system) and participant.